Skip to main content

Table 3 Clinicopathological and genetic characteristics of Omani CRC cases.

From: Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study

  Omani     
  All non-MSI-H MSI-H Odds Ratio P
Number of patients 61 53 (87)a 8 (13)a   
Mean Age 52.7+13.6
-
53.1+12.8
-
51.5+19.2
-
  0.76
Gender      0.37
   Female 24 (39) 22 (42) 2 (25) 1  
   Male 37 (61) 31(58) 6 (75) 2.12(0.39–11.55)  
Site 61     0.75
   Distal 51 (84) 44(83) 7(87) 1  
   Proximal 10 (16) 9(17) 1(13) 1.43(0.16–13.11)  
Mucin Production 61     0.44
   None 47 (77) 42(78) 5 (63) 1  
   < 50% 14(23) 11 (20) 3(37) 2.3(0.47–11.10)  
   > 50% 0 0 0 NA  
Differentiation 60     0.44
   Well 7 (12) 7 (14) 0 NA  
   Moderate 49(82) 43 (81) 6(86) 1  
   Poor 4 (6) 3 (6) 1 (14) 2.39(0.21–26.84)  
Stage 61     0.28
   Stage 1 1 (2) 1 (2) 0 NA  
   Stage 2 20 (33) 15 (28) 5 (62) 1  
   Stage 3 31 (50) 29 (55) 2 (25) 0.21(0.02–1.50)  
   Stage 4 9 (15) 8 (15) 1 (13) 0.38(0.01–4.41)  
BRAF 59     0.62
   Wild type 48 (81) 42 (82) 6 (75) 1  
   V600E 11 (19) 9 (18) 2 (25) 1.56(0.27–9.0)  
hMLH1 methylation (MSP) 49     0.47
   Unmethylation 8 (16) 6(14.6) 2 (25) 1  
   Methylation 41 (84) 35 (85.4) 6 (75) 0.51(0.08–3.17)  
p16 methylation (MSP) 44     0.09
   Unmethylation 27(62) 20 (56) 7 (88) 1  
   Methylation 17 (38) 16 (44) 1 (12) 0.18(0.02–1.61)  
hMLH1 expression by IHC 61     0.68
   Normal 42 (69) 37(70) 5 (62) 1  
   Negative 19 (32) 16 (30) 3(38) 1.39(0.29–6.67)  
hMSH2 expression by IHC 61     0.63
   Normal 56 (92) 49 (92) 7(87) 1  
   Negative 5 (8) 4 (8) 1(13) 1.75(0.17–16.67)  
  1. Parentheses indicate percentages: All values are based on column except a based on row. MSP = methylation-specific PCR; IHC = immunohistochemistry